Ā | Azacitidine (nā=ā288) | Decitabine (nā=ā199) | p-value |
---|---|---|---|
Demographic characteristics | |||
Age, mean (SD) | 70.3Ā years (11.8) | 69.4Ā years (11.6) | 0.3890 |
18-64Ā years old | 25.3 | 28.6 | -- |
65+ years old | 74.7 | 71.4 | -- |
Gender (% male) | 59.0 | 54.8 | 0.3510 |
Insurance Type | Ā | Ā | 0.2450 |
Commercial Insurance (%) | 46.5 | 41.2 | -- |
Medicare Advantage (%) | 53.5 | 58.8 | -- |
Clinical characteristics | |||
MDS diagnosis *, % | 54.5 | 51.9 | 0.549 |
RBC transfusion*, % | 51.0 | 54.8 | 0.4185 |
ESA utilization** | 26.4 | 25.1 | 0.754 |
G/GM-CSF utilization** | 18.1 | 19.1 | 0.771 |
Charlson Comorbidity Index* mean (SD) | 3.0 (1.7) | 3.4 (1.8) | 0.0140 |
Hospitalization* | 61.5 | 70.9 | 0.0323 |